Showing results (31-40 of 135) with videos related to

Sort By:
Pageof 14
JAMA Otolaryngology-- Head & Neck Surgery|April 3, 2025
Cost of Neoadjuvant Immunotherapy vs Up-Front Surgery in Cutaneous Squamous Cell Carcinoma: A Post Hoc Analysis of a Nonrandomized Clinical TrialShannon S Wu, A Dimitrios Colevas, Luis Martinez Ramirez, et al.
Head & Neck|April 17, 2014
Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatinA Dimitrios Colevas, Ruth R Lira, Electra A Colevas, et al.
Investigational New Drugs|April 18, 2022
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skinLuke S McLean, Tessa A Morris, Ann Gramza, et al.
Oral Oncology|August 9, 2003
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II studyRobert Haddad, A Dimitrios Colevas, Jeffrey F Krane, et al.
Cancer Biology & Therapy|April 26, 2007
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinomaEdwin M Posadas, Samir Undevia, Elizabeth Manchen, et al.
Head & Neck|July 18, 2024
Nasopharyngeal cancer mortality in disaggregated Asian and non-Asian AmericansGeorge A Hung, Sanah Vohra, Gina Kim, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|July 18, 2018
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell CarcinomaMisha Amoils, Jinah Kim, Carolyn Lee, et al.
British Journal of Haematology|August 12, 2008
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphomaOwen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111Maha Hussain, Catherine M Tangen, Primo N Lara, et al.
Ophthalmic Plastic and Reconstructive Surgery|November 19, 2021
Genome Sequencing and Apoptotic Markers to Assess Treatment Response of Lacrimal Gland Adenoid Cystic Carcinoma to Intra-Arterial Cytoreductive ChemotherapyMichael D Yu, Clara J Men, Huy Do, et al.
Pageof 14